PARIS—U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1 percent stake in French vaccines company, as the companies announced developments in their partnership to tackle the Lyme disease.
Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.
